Effects of tolbutamide on growth and body composition of nondiabetic children with cystic fibrosis.
Previously, we reported that nondiabetic children with cystic fibrosis show a blunted insulin response to a meal stimulus. In the study presented here, using tolbutamide, we determined the effects of augmented insulin secretion/action on height and lean body mass of children with cystic fibrosis. Twelve subjects (mean +/- SEM age, 11.0 +/- 0.5 y) were studied for three 4-mo periods: 1) pretreatment, 2) treatment, consisting of 750 mg/d of tolbutamide, and 3) posttreatment. Before the pretreatment period, insulin response to a meal stimulus was evaluated in relation to three doses of tolbutamide: 0, 250, and 500 mg. Growth was monitored during each period, and incremental changes in lean body mass were calculated from height data. To validate the change in lean body mass based on height measurements, we determined lean body mass in seven subjects during the treatment period by using a criterion method (H218O). Growth velocity (cm/4 mo) significantly increased (p less than 0.05) during the treatment (2.58 +/- 0.31) compared with the pretreatment period (0.88 +/- 0.20). The increase in lean body mass calculated from height was greater during the treatment (1.61 +/- 0.29 kg/4 mo) than during the pretreatment period (0.44 +/- 0.18 kg/4 mo) (p less than 0.05). There was also a significant increase (p less than 0.05) in lean body mass during the treatment as measured with H218O (1.91 +/- 0.65 kg/4 mo). Acute administration of either 250 or 500 mg of tolbutamide reduced (p less than 0.05) the area under the glucose concentration curve in response to a meal compared with the control condition of no tolbutamide.(ABSTRACT TRUNCATED AT 250 WORDS)
Zipf
W B
WB
Department of Pediatrics, Ohio State University College of Medicine, Columbus 43205.
Kien
C L
CL
Horswill
C A
CA
McCoy
K S
KS
O'Dorisio
T
T
Pinyerd
B L
BL
D000293:Adolescent; D001786:Blood Glucose; D001823:Body Composition / Q000187:drug effects*; D002648:Child; D003550:Cystic Fibrosis / Q000378:metabolism*; D005260:Female; D006128:Growth / Q000187:drug effects*; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D014044:Tolbutamide / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D014044:Tolbutamide